Last updated: October 2026
Key points in 60 seconds
About half the world's population is projected to be myopic by 2050, and the proportion with high myopia is rising fastest. Myopia control is now a routine paediatric consultation. The evidence has moved quickly in the last three years, especially for atropine, which turned out more modest at 0.01% than many hoped.
| Intervention | What the evidence shows | Practical notes |
|---|---|---|
| Outdoor time | Delays onset; about 40–80 extra minutes a day is associated with lower incidence. A weaker effect once myopia has started. | Free, safe, and advised for every child. |
| Low-dose atropine | LAMP (Hong Kong): 0.05% was the most effective of 0.05%, 0.025% and 0.01%. LAMP2: 0.05% reduced new-onset myopia in pre-myopic children. CHAMP, PEDIG and MOSAIC: modest effect of 0.01% alone in more diverse populations. | Many clinicians now prefer 0.025–0.05%. Effect depends on formulation. Taper rather than stop abruptly to limit rebound. |
| Lenslet (defocus) spectacles | DIMS (MiyoSmart) and HAL (Stellest) slow axial elongation by roughly 30–50%. Stellest received FDA authorisation in September 2025 for children aged 6–12 at the start of treatment. For every spectacle design side by side (DIMS, HAL, DOT, CARE, prismatic bifocals) and how to fit them, see myopia-control spectacle lenses. | Good first option for younger children. Requires full-time wear and good centration. Long-term data now extend to 6–8 years. |
| Dual-focus soft contact lenses | MiSight 1 day (FDA 2019): 0.73 D (59%) less progression and 0.32 mm (52%) less axial growth over 3 years, with benefit through 6 years and no rebound reported. | Daily disposable. Suits motivated children from about age 8. |
| Orthokeratology | Reduces axial elongation by about 0.2–0.3 mm over 2 years. | Overnight wear carries a risk of microbial keratitis (including Acanthamoeba), so hygiene teaching is essential. |
| Repeated low-level red light (RLRL) | Large short-term effects in Chinese trials, including combined with ortho-k. | Safety is uncertain: retinal injury has been reported, some devices may exceed exposure limits, and rebound after stopping is a concern. Devices are not FDA-cleared. Do not combine with atropine (larger pupil). |
Related: atropine 0.01% eye drops in myopia, understanding myopia and amblyopia treatment updates.
📘 Want more exam-ready material? See Most Commons in Ophthalmology on Kindle, or browse all my books.
How to cite this page
Patel D. Myopia Control in 2026: Atropine, Lenslet Spectacles, Ortho-K and Red Light. RPC Rounds (Sadbhaav Eye Clinic). Updated October 2026. Available at: https://www.sadbhaavclinic.com/myopia-control-2026.html. Accessed [date].
Looking for an eye specialist in Ahmedabad? Read about children's eye check-ups at Sadbhaav or book a consultation with Dr. Dhaval Patel.